176 related articles for article (PubMed ID: 23960167)
1. The 26-week Tg.rasH2 mice carcinogenicity studies: microscopic examination of only select tissues in low- and mid-dose groups.
Paranjpe MG; Denton MD; Elbekai RH
Toxicol Pathol; 2014 Oct; 42(7):1153-7. PubMed ID: 23960167
[TBL] [Abstract][Full Text] [Related]
2. Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice.
Takaoka M; Sehata S; Maejima T; Imai T; Torii M; Satoh H; Toyosawa K; Tanakamaru ZY; Adachi T; Hisada S; Ueda M; Ogasawara H; Matsumoto M; Kobayashi K; Mutai M; Usui T
Toxicol Pathol; 2003; 31(2):191-9. PubMed ID: 12696579
[TBL] [Abstract][Full Text] [Related]
3. Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice.
Yamamoto S; Mitsumori K; Kodama Y; Matsunuma N; Manabe S; Okamiya H; Suzuki H; Fukuda T; Sakamaki Y; Sunaga M; Nomura G; Hioki K; Wakana S; Nomura T; Hayashi Y
Carcinogenesis; 1996 Nov; 17(11):2455-61. PubMed ID: 8968063
[TBL] [Abstract][Full Text] [Related]
4. Examination of percutaneous application in a 26-week carcinogenicity test in CB6F1-TG rasH2 mice.
Urano K; Suzuki S; Machida K; Eguchi N; Sawa N; Kikuchi K; Hattori Y; Usui T
J Toxicol Sci; 2007 Oct; 32(4):367-75. PubMed ID: 17965551
[TBL] [Abstract][Full Text] [Related]
5. Reduction in the number of animals and the evaluation period for the positive control group in Tg.rasH2 short-term carcinogenicity studies.
Shah SA; Paranjpe MG; Atkins PI; Zahalka EA
Int J Toxicol; 2012; 31(5):423-9. PubMed ID: 22988008
[TBL] [Abstract][Full Text] [Related]
6. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
7. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies.
Mitsumori K; Koizumi H; Nomura T; Yamamoto S
Toxicol Pathol; 1998; 26(4):520-31. PubMed ID: 9715511
[TBL] [Abstract][Full Text] [Related]
8. Tg.rasH2 Mice and not CByB6F1 Mice Should Be Used for 28-Day Dose Range Finding Studies Prior to 26-Week Tg.rasH2 Carcinogenicity Studies.
Paranjpe MG; Belich J; Vidmar TJ; Elbekai RH; McKeon M; Brown C
Int J Toxicol; 2017; 36(4):287-292. PubMed ID: 28553733
[TBL] [Abstract][Full Text] [Related]
9. Twenty-six-Week carcinogenicity study of chloroform in CB6F1 rasH2-transgenic mice.
Sehata S; Maejima T; Watanabe M; Ogata S; Makino T; Tanaka K; Manabe S; Takaoka M
Toxicol Pathol; 2002; 30(3):328-38. PubMed ID: 12051550
[TBL] [Abstract][Full Text] [Related]
10. Regulatory Forum Opinion Piece*: Retrospective Evaluation of Doses in the 26-week Tg.rasH2 Mice Carcinogenicity Studies: Recommendation to Eliminate High Doses at Maximum Tolerated Dose (MTD) in Future Studies.
Paranjpe MG; Denton MD; Vidmar TJ; Elbekai RH
Toxicol Pathol; 2015 Jul; 43(5):611-20. PubMed ID: 25391312
[TBL] [Abstract][Full Text] [Related]
11. Twenty-six week carcinogenicity study of ampicillin in CB6F1-TgrasH2 mice.
Adachi T; Kuwamura Y; Fujiwara T; Tanimoto N; Nishimura T; Koguchi A; Kobayashi K; Sasaki Y; Yamaguchi C; Honda T; Kawashima K; Yuasa H; Yamamura T; Inui T
J Toxicol Sci; 2002 Aug; 27(3):147-63. PubMed ID: 12238139
[TBL] [Abstract][Full Text] [Related]
12. Historical control data of spontaneous tumors in transgenic CByB6F1-Tg(HRAS)2Jic (Tg.rasH2) mice.
Paranjpe MG; Elbekaei RH; Shah SA; Hickman M; Wenk ML; Zahalka EA
Int J Toxicol; 2013; 32(1):48-57. PubMed ID: 23324159
[TBL] [Abstract][Full Text] [Related]
13. Twenty-six-week carcinogenicity study of sulfamethoxazole in CB6F1-Tg-rasH2 mice.
Torii M; Itoh F; Yabuuchi K; Ohno K; Kominami G; Hirano K; Tasaki T; Nara H
J Toxicol Sci; 2001 May; 26(2):61-73. PubMed ID: 11429969
[TBL] [Abstract][Full Text] [Related]
14. Proposal to Eliminate Urethane-Treated Positive Control Dose Groups in 26-Week Tg.rasH2 Carcinogenicity Studies.
Paranjpe MG; Rudmann D; Sargeant A; Morse M; Yonpiam R; Bonnette K; Albretsen J; Papagiannis C
Int J Toxicol; 2021; 40(3):207-210. PubMed ID: 33813924
[TBL] [Abstract][Full Text] [Related]
15. NTP technical report on the toxicology and carcinogenesis studies of Elmiron (Cas No. 37319-17-8) in F344/N rats and B6C3F1 mice (Gavage Studies).
National Toxicology Program, Public Health Services, National Institutes of Health, US Department of Health and Human Services,
Natl Toxicol Program Tech Rep Ser; 2004 May; (512):7-289. PubMed ID: 15213766
[TBL] [Abstract][Full Text] [Related]
16. A Comparison of Spontaneous Tumors in Tg.rasH2 Mice in 26-week Carcinogenicity Studies Conducted at a Single Test Facility during 2004 to 2012 and 2013 to 2018.
Paranjpe MG; Belich JL; Mann PC; McKeon ME; Elbekai RH; Brown CM; Patrick DJ
Toxicol Pathol; 2019 Jan; 47(1):18-25. PubMed ID: 30407148
[TBL] [Abstract][Full Text] [Related]
17. The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
Tamaoki N
Toxicol Pathol; 2001; 29 Suppl():81-9. PubMed ID: 11695564
[TBL] [Abstract][Full Text] [Related]
18. CB6F1-rasH2 mouse: overview of available data.
Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
[TBL] [Abstract][Full Text] [Related]
19. Carcinogenic susceptibility to N-bis(2-hydroxypropyl)nitrosamine (DHPN) in rasH2 mice.
Okamura M; Moto M; Kashida Y; Machida N; Mitsumori K
Toxicol Pathol; 2004; 32(4):474-81. PubMed ID: 15223773
[TBL] [Abstract][Full Text] [Related]
20. Use of IC tags in short-term carcinogenicity study on CB6F1 TGrasH2 mice.
Urano K; Suzuki S; Machida K; Sawa N; Eguchi N; Kikuchi K; Fukasawa K; Taguchi F; Usui T
J Toxicol Sci; 2006 Dec; 31(5):407-18. PubMed ID: 17202757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
